Summary
Eli Lilly and Company (LLY) filed an 8-K report detailing the results of its 2023 Annual Meeting of Shareholders held on May 1, 2023. The report indicates strong shareholder participation, with approximately 90% of outstanding shares represented. Key outcomes include the election of four director nominees to three-year terms and the advisory approval of executive compensation. Shareholders also voted to continue advisory votes on executive compensation on an annual basis and ratified the appointment of Ernst & Young LLP as the independent auditor. Notably, proposals to eliminate the company's classified board structure and to remove supermajority voting provisions did not achieve the required 80% shareholder approval. Several shareholder proposals concerning lobbying activities, patent exclusivity impacts, abortion support risks, diversity and inclusion efforts, and political expenditure reporting were also not approved.
Key Highlights
- 1Strong shareholder turnout of approximately 90% of outstanding shares at the 2023 Annual Meeting.
- 2All four director nominees were successfully elected to serve three-year terms.
- 3Shareholders provided advisory approval for the compensation of named executive officers.
- 4The company will continue to hold annual advisory votes on executive compensation, as supported by shareholder vote.
- 5Ernst & Young LLP was ratified as the independent auditor for 2023.
- 6Proposals to declassify the board and eliminate supermajority voting provisions failed to garner the required 80% shareholder approval.
- 7Multiple shareholder proposals covering diverse topics such as lobbying, patent strategy, and DEI were not approved.